XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Cash flows from operating activities:      
Net cash provided by (used in) operating activities   $ 70,631 $ 223,157
Cash flows from investing activities:      
Proceeds from sale of property and equipment   34 65
Purchases of property and equipment   (2,869) (4,388)
Purchases of equity securities   (32,558) (67,733)
Purchases of available-for-sale debt securities   (103,560) (178,788)
Proceeds from sales of equity securities $ 5,597 42,830 26,667
Proceeds from sales of available-for-sale debt securities   3,985 24,855
Maturities of available-for-sale debt securities   77,676 59,291
Net cash provided by (used in) investing activities   (14,462) (140,031)
Cash flows from financing activities:      
Debt issuance costs paid   0 (131)
Preferred stock dividend   (8) (8)
Common stock dividend   (14,679) (14,880)
Purchase of treasury stock   (18,385) (9,800)
Payments related to tax withholding for share-based compensation   (314) (209)
Repayment of debt   (1,104) (1,103)
Net cash provided by (used in) financing activities   (34,490) (26,131)
Cash and cash equivalents and restricted cash and cash equivalents:      
Net increase (decrease) during the period   21,679 56,995
Balance, beginning of period   391,341 253,143
Balance, end of period 413,020 413,020 310,138
Cash and cash equivalents, and restricted cash and cash equivalents within the Consolidated Balance Sheets      
Cash and cash equivalents 343,532 343,532  
Restricted cash and cash equivalents 69,488 [1] 69,488 [1]  
Total cash and cash equivalents and restricted cash and cash equivalents $ 413,020 $ 413,020 $ 310,138
[1] See “—Note 5 (Insurance Operations)” for a discussion of the nature of the restrictions for restricted cash and cash equivalents and "—Note 14(Variable Interest Entities)” for a discussion of restricted cash held in a trust account.